Designed for More Than Launch: Accelerating Biosimilar Manufacturing at Scale

Bringing biosimilars to market efficiently means making smart decisions early—especially around when to intensify your process and when to scale. In this webinar, you’ll explore how to confidently navigate those choices and set your manufacturing strategy up for long‑term success.

In this webinar with Cytiva we will walk you through practical approaches to process intensification and scale‑up, tailored to different facility footprints and portfolio goals. Whether you’re working within limited space or planning for multiple biosimilars, you’ll gain insight into strategies that can accelerate development while keeping costs under control.

You’ll also learn how to think proactively about cost of goods from the very beginning—so you’re ready to scale production smoothly, respond to market demand, and avoid costly rework down the line. Most importantly, this session will empower you to build efficient, flexible processes that help get high‑quality biosimilars to your target markets.

Presented by Mark Schofield, Cytiva, Director Science

Mark Schofield leads a team of scientists and engineers to fundamentally understand how separations work and apply that knowledge to challenging purifications. He is happiest guiding technology and innovation through an understanding of applications. But more recently, has been driving thought leadership and building bridges to better serve science and the biopharmaceutical industry!

Ingrid Long, Cytiva, Global Product Manager Bioprocess Downstream Hardware

Ingrid Long is a Global Product Manager for continuous chromatography hardware at Cytiva, with over 20 years experience in downstream process development and product design. In her current role, Ingrid works at the intersection of product strategy, technology development, and customer needs, helping translate complex process challenges into scalable, future‑ready solutions.

Followed by a live question and answer session

Sponsored by Cytiva

At Cytiva, our mission is to advance and accelerate the development of therapeutics. With nearly 16,000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma, and contract manufacturers. Learn more at cytiva.com.